- Home
- SES vs AUTL Comparison
SES vs AUTL Comparison
Compare SES & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- AUTL
- Stock Information
- Founded
- SES 2012
- AUTL 2014
- Country
- SES United States
- AUTL United Kingdom
- Employees
- SES N/A
- AUTL N/A
- Industry
- SES Auto Parts:O.E.M.
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SES Consumer Discretionary
- AUTL Health Care
- Exchange
- SES Nasdaq
- AUTL Nasdaq
- Market Cap
- SES 384.0M
- AUTL 415.2M
- IPO Year
- SES N/A
- AUTL 2018
- Fundamental
- Price
- SES $2.75
- AUTL $1.51
- Analyst Decision
- SES Buy
- AUTL Strong Buy
- Analyst Count
- SES 1
- AUTL 5
- Target Price
- SES $2.00
- AUTL $9.12
- AVG Volume (30 Days)
- SES 15.8M
- AUTL 4.6M
- Earning Date
- SES 10-30-2025
- AUTL 11-11-2025
- Dividend Yield
- SES N/A
- AUTL N/A
- EPS Growth
- SES N/A
- AUTL N/A
- EPS
- SES N/A
- AUTL N/A
- Revenue
- SES $11,360,000.00
- AUTL $29,934,000.00
- Revenue This Year
- SES $883.92
- AUTL $641.63
- Revenue Next Year
- SES $159.98
- AUTL $109.21
- P/E Ratio
- SES N/A
- AUTL N/A
- Revenue Growth
- SES N/A
- AUTL 185.17
- 52 Week Low
- SES $0.20
- AUTL $1.11
- 52 Week High
- SES $3.05
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- SES 83.76
- AUTL 46.20
- Support Level
- SES $1.57
- AUTL $1.56
- Resistance Level
- SES $2.01
- AUTL $1.65
- Average True Range (ATR)
- SES 0.25
- AUTL 0.10
- MACD
- SES 0.09
- AUTL 0.03
- Stochastic Oscillator
- SES 82.51
- AUTL 54.84
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.